In this video, Regina Barragán-Carrillo, MD, of City of Hope, details progress in the treatment of metastatic renal cell carcinoma (RCC), highlighting how survival rates have improved significantly over the past two decades. She discusses the transformative impact of immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 agents, and their use in combination with tyrosine kinase inhibitors (TKIs) or as dual ICI regimens. These advances have led to longer survival, enhanced quality of life, and a broader range of therapeutic options. The conversation also addresses the complexities of treatment selection, particularly in first-line therapy and the challenges of managing ...
Advanced Renal Cell Carcinoma
Advertisement
Latest News
The panelists discuss promising new advancements and novel therapies for treating RCC, including LAG-3 and CAR-T therapies.
The panel discusses how designing effective trials could refine the approach to treatment strategies for RCC.
Part 3 of this roundtable examines adjuvant pembrolizumab and the role of TKIs in treatment sequencing for RCC.
The panelists examine the data on TKIs and immunotherapy for RCC from the TiNivo-2 trial.
Part 1 of this roundtable examines the key differences between the CONTACT-03 and TiNivo-2 trials.
Drs. Beckermann and Barata explore the implications of the negative findings of the CONTACT-03 trial on clinical practice.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
Advertisement
Section Editor
Katy Beckermann, MD, PhDGenitourinary Medical Oncologist | Vanderbilt-Ingram Cancer Center
Advertisement
Get the latest RCC research straight to your inbox.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.